Financial Personal
MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002
Met primary endpoint of safety: MH002 was safe and well tolerated with no evidence of adverse reactions when administered for 8 weeks. Clinical remission rate of 46% at week 8, a mean decrease in the modified Pouchitis Disease Activity Index (mPDAI)
GHENT, Belgium -- MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis. Read More
Related
Share this page
Guest Posts by Easy Branches